Aspira Women's Health Inc. · OTC:AWHL

Aspira Women's Health — Investor Day (May 2023)

29 slides from Aspira Women's Health's investor day presentation, May 23, 2023

  1. Slide 1: Aspira Investor Day: OvaWatch and EndoCheck Market Opportunities

    Aspira Investor Day OvaWatchSM and EndoCheckTM Market Opportunities May 23, 2023

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. These forward-looking statements include, am

  3. Slide 3: Your Speakers Today – Our Invited Guest Clinicians

    Your Speakers Today – Our Invited Guest Clinicians Dr. Tamika Sea, FACOG Obstetrician, gynecologist and Founder/Owner of Advanced Women’s Care Center in Atlanta, Georgia Dr. Kevin Elias Assistant Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School and Director of G

  4. Slide 4: Your Speakers Today – Aspira Science and Medical Leaders

    Your Speakers Today – Aspira Women’s Health Science and Medical Leaders Dr. Charles Dunton Gynecologic Oncologist and Chair of Aspira’s Scientific Advisory Board Dr. Ryan Phan Chief Scientific and Chief Operating Officer 4

  5. Slide 5: About Aspira Women's Health

    About Aspira Women’s Health Aspira is dedicated to improving health outcomes through the development and distribution of technology-enabled tools for the diagnosis of gynecologic disease Commercial Revenue producing blood tests processed in a CLIA-certified laboratory Tests environment Strong Growth

  6. Slide 6: Endometriosis

    Endometriosis OvaMDxTM EndoMDxTM Serial MonitoringTM Commercially Commercially In development Planned In development available available Planned test expansion launch 2023 with Dana-Farber for indeterminate for adnexal launch 2023 licensed from first ever Cancer Institute and likely benign masses pl

  7. Slide 7: Current portfolio offers providers an ovarian cancer risk assessment tool

    Nearly 80,000 tests performed Current portfolio offers providers an ovarian cancer risk assessment tool for any woman with an adnexal mass Machine Learning Algorithm Optimized Multivariate Index Assay Optimized Towards Negative Predictive Value (NPV) for Surgical Triaging to Assess Ovarian Cancer Ri

  8. Slide 8: Ovarian Cancer: The Clinician's Perspective

    Ovarian Cancer: The Clinician’s Perspective Dr. Charles Dunton Dr. Tamika Sea Copyright © Aspira Women’s Health® Inc. 2023. All Rights Reserved.

  9. Slide 9: Adnexal Masses, Oophorectomies, and Ovarian Cancer Cases

    Adnexal Masses, Oophorectomies, and Ovarian Cancer Cases • An adnexal mass is a mass of the ovary, fallopian tube, or surrounding tissues. • While up to 1 in 5 women will develop an adnexal mass in their lifetime, most are benign. • HCPs need reliable, non-invasive tools to understand the difference

  10. Slide 10: Indeterminate Masses are a Current Diagnostic Dilemma

    Indeterminate Masses are a Current Diagnostic Dilemma Pelvic mass detected on ultrasound1 Probably Benign Uncertain Likely Malignant 18-31% of masses (>50% in some clinical settings) are indeterminate2-4 Watchful waiting Referral management What’s What’s to Gynecological of symptoms the Risk? the Ri

  11. Slide 11: 1,283 Radiology Reports from Patients with Known Surgical Pathology Results

    1,283 Radiology Reports from Patients with Known Surgical Pathology Results were Independently Analyzed in Blinded Reviews by 2 Of 5 Experienced Clinicians Clinical Clinical Introduction and Objectives N % Concordance? Impression 1* Impression 2* Benign Benign 224 20.66% Yes • Pelvic ultrasound is t

  12. Slide 12: Lack of Effective Diagnostic Tools Result in Negative Outcomes

    Lack of Effective Diagnostic Tools Result in Negative Outcomes FOR PATIENTS Assessed Risk is Low; Malignancy is Present Assessed Risk is High; No Malignancy is Present Higher Mortality Unnecessary treatment or surgery • Delays in diagnosis and treatment • Unnecessary or premature surgery • Higher mo

  13. Slide 13: A Typical Clinical Management of Suspicious Ovarian Cancer Patient

    A Typical Clinical Management of Suspicious Ovarian Cancer Patient Patient presents Internet Search She visits her Complete workup While waiting for At the ultrasound with vague tells her it could ObGyn and includes orders her appointment, appointment, they abdominal be anything from mentions her fo

  14. Slide 14: Serial Monitoring and Research Update

    Serial Monitoring and Research Update Dr. Ryan Phan Copyright © Aspira Women’s Health® Inc. 2023. All Rights Reserved.

  15. Slide 15: OvaWatch Serial Monitoring Test Expansion in 2H2023

    OvaWatch Serial Monitoring Test Expansion in 2H2023 OvaWatch will be the only biomarker-based assay available to assist healthcare providers in monitoring adnexal masses • OvaWatch was intended as both a point-in-time risk assessment and mass monitoring application • Aspira continues to monitor and

  16. Slide 16: Example Report - Not real patient data

    Example Report - Not real patient data 1.1 1.0 1.2 1.3 1.1 Copyright © Aspira Women’s Health® Inc. 2023. All Rights Reserved. 16

  17. Slide 17: 3 Abstracts Accepted for Publication 2023 ASCO

    New Publications 3 Abstracts Accepted for Publication 2023 American Society of Clinical Oncology (ASCO) e17607: Multivariate index assay (MIA3G) to reduce preventive surgery for ovarian cancer >> Reducing surgical backlog e17608: Serial monitoring of ovarian cancer risk in women with adnexal mass >>

  18. Slide 18: Future Directions: microRNA & Ovarian Cancer

    Future Directions: microRNA & Ovarian Cancer Dr. Kevin Elias Copyright © Aspira Women’s Health® Inc. 2023. All Rights Reserved. 18

  19. Slide 19: miRNAs as Complementary Biomarkers for Non-Invasive Diagnostics

    miRNAs as Complementary Biomarkers for Non-Invasive Diagnostics Advantages of miRNA • Detectable in all body fluids • Stable at room temperature Developing new tests means • Amenable to amplification through PCR expanding the genome • Easy to multiplex • Can be correlated to disease biology 1. Uchid

  20. Slide 20: Endometriosis: A Significant Unmet Need

    Endometriosis: A Significant Unmet Need Copyright © Aspira Women’s Health® Inc. 2023. All Rights Reserved.

  21. Slide 21: Endometriosis: A debilitating disease impacting 6 million American women

    Endometriosis: A debilitating disease impacting 6 million American women Endometriosis is a condition in which tissue similar to the lining of the uterus grows outside the uterus. • Untreated endometriosis leads to pain, New Treatment Options Require Dx excessive menstrual bleeding, digestive distre

  22. Slide 22: Endometriosis is a top-of-mind issue for women

    Endometriosis is a top-of-mind issue for women Copyright © Aspira Women’s Health® Inc. 2023. All Rights Reserved. 22

  23. Slide 23: EndoCheck Assay Features

    Assay for noninvasive diagnosis of endometriosis Aspira’s Advantages EndoCheck Assay Features FDA-approved Used by healthcare providers to aid in diagnosis and treatment of platform endometriosis Validating in CLIA/CAP/NY/CA • Noninvasive, blood-based assay utilizing multiple, differentiating state-

  24. Slide 24: Launch Timeline

    Launch Timeline • EndoCheck’s is being validated in the same CLIA lab environment that it will be processed commercially. • Completion of validation is in final stages for completion in early Q3. • Multi-site clinical study launched in 2022 will provide additional clinical data supporting launch – M

  25. Slide 25: Future Directions: microRNA & Endometriosis

    Future Directions: microRNA & Endometriosis Dr. Kevin Elias Copyright © Aspira Women’s Health® Inc. 2023. All Rights Reserved. 25

  26. Slide 26: Aspira's Market Opportunity

    Aspira’s Market Opportunity Nicole Sandford Copyright © Aspira Women’s Health® Inc. 2023. All Rights Reserved.

  27. Slide 27: >$1B Annual Revenue Potential from Current and Near-Term Products

    >$1B Annual Revenue Potential from Current and Near-Term Products Endo Portfolio OvaMDxTM EndoMDxTM Serial MonitoringTM 1.2-1.5M patients 200-400K patients 2.0-3.0M patients 1.2-1.5M patients Est. 6M patients in Est. 6M patients in per year per year per year per year the U.S. the U.S. $225M-265M $35

  28. Slide 28: Our Path Forward Remains Clear

    Our Path Forward Remains Clear 2023 is about Continued Growth and Execution Continue 20%+ Growth Adoption and Accelerate Reimbursement Development Serial Monitoring Operational Excellence & Cost Containment Copyright (C) Aspira Women's Health Inc., 2023. All Rights Reserved. 28

  29. Slide 29: Questions?

    Questions? Copyright © Aspira Women’s Health® Inc. 2023. All Rights Reserved. 29

Aspira Women's Health — Investor Day (May 2023) on 6ix